This article was originally published in The Rose Sheet
Swiss fragrance and flavors company recently introduced Cosmone, a "novel" fragrance ingredient described as an "intensely rich, powerful and elegant musk," firm announces in first quarter earnings release. Slow retail sales during the 2008 holiday season in North America and Europe led to destocking of fine fragrances in the quarter, resulting in a decline in total fragrance sales of 10.4 percent (5.4 percent in local currencies) to $382.3 million (CHF1=$.87), company reports. Lack of consumer confidence and reduced travel is likely to impact fine fragrance sales throughout 2009, firm notes. Net sales for the period declined 7.3 percent (2.6 percent in local currencies) to $850.7 million, Givaudan reports. Despite first quarter performance, Givaudan expects its total fragrance and flavors businesses will outgrow the underlying market
You may also be interested in...
Beauty Market News: China Cosmetics Regulations Modernized, Florida Stops Local Oxybenzone Bans, More
L’Oreal acquires Thayers Natural Remedies; Unilever, L’Oreal remove ‘whitening,’ ‘fair’ from labels; China finalizes modernization of cosmetics regulations; and Florida governor signs law preventing local bans on oxybenzone.
The US Food and Drug Administration should require that outsourcing facilities collect bioavailability data for compounded bioidentical hormone replacement therapy products, while compounding pharmacies should be required to report adverse events to state pharmacy boards and the FDA. Such actions would help resolve some of the safety concerns for these products, says a 1 July report from the National Academy of Sciences, Engineering and Medicine.
Some analysts see a 50-50 chance of US FDA approval despite the controversial dataset for the anti-amyloid antibody, but at least one expects an eventual CRL requesting a third Phase III trial.